NSE: FORTIS · 7 October 2026
- Fortis Healthcare Ltd (FORTIS) shares rose 1.98% on Tuesday, closing at ₹779.10 against a previous close of ₹764.00. The stock traded within a daily range of ₹753.45 and ₹782.45 after opening at ₹761.15.
- The Supreme Court of India disposed of the Special Leave Petition filed by Fortis Healthcare challenging the Delhi High Court's order directing a forensic audit. The apex court allowed the forensic audit to proceed independently while clarifying that prior observations in the judgment were tentative and shall not influence the audit outcome.
- Trading volume was 1.05 times the 20-day average daily volume.
Why is Fortis Healthcare share price rising on 7 October 2026?
Fortis Healthcare Ltd (FORTIS) shares rose 1.98% on Tuesday, closing at ₹779.10 against a previous close of ₹764.00. The stock traded within a daily range of ₹753.45 and ₹782.45 after opening at ₹761.15.
The broader market exhibited weakness, with the Nifty falling 0.76% and the Nifty Pharma sector benchmark declining 0.43%. Fortis outperformed both the broader index and its sector benchmark during the session, registering positive momentum despite a soft broader market backdrop.
Company disclosures provide ongoing context regarding legal developments, including the Supreme Court's September order allowing a forensic audit to proceed while clarifying that previous observations remain tentative and independent. Additionally, the company recently announced definitive agreements via its subsidiary Fortis Hospotel Ltd to provide healthcare services to a 400+ bedded hospital in Ashok Vihar, New Delhi, alongside a loan agreement of up to ₹567 crore for project development.
18.17 lakh shares traded by 7 October 2026 · 03:15 PM IST. This compares with a 20-day average daily volume of 17.39 lakh shares (1.05 times). The five-day average daily volume was 32.25 lakh shares. Separately, the NSE report for 6 October 2026 showed 6.55 lakh shares delivered, representing 52.49% of that day’s traded volume. The same report recorded 37,655 trades.
Fortis gained 1.98% on moderate trading volume of 18.17 lakh shares (1.05x the 20-day average volume), outperforming a declining broader market and sector benchmark. Recent strategic expansions, such as the Ashok Vihar hospital service agreement, and ongoing legal clarity regarding the Supreme Court's forensic audit order provide constructive fundamental backdrop, though no single direct catalyst triggered today's specific uptick.
Latest Company Developments
The Supreme Court of India disposed of the Special Leave Petition filed by Fortis Healthcare challenging the Delhi High Court's order directing a forensic audit. The apex court allowed the forensic audit to proceed independently while clarifying that prior observations in the judgment were tentative and shall not influence the audit outcome.
Provides regulatory and legal clarity regarding ongoing court proceedings involving historical promoter matters while confirming that no liability or fine has been imposed on the company.
Fortis Hospotel Limited, a wholly-owned subsidiary of Fortis Healthcare, entered into definitive agreements with Seth Sunder Lal Jain Charitable Eye Hospital to provide healthcare services to a planned 400+ bedded super-specialty hospital in Ashok Vihar, New Delhi. Under a 29-year Healthcare Services Agreement, the subsidiary will provide clinical services and specialized equipment, supported by a phased loan of up to ₹567 crore for infrastructure development.
Expands the company's long-term operational footprint in the Delhi-NCR healthcare market and strengthens future revenue visibility.
Order Passed By The Hon Ble Delhi High Court In Relation To Certain Applications Filed By Daiichi Sankyo Company, Limited Inter Alia The Company. Detailed Disclosure Is Attached.
a press release dated August 06, 2026, titled "Fortis Healthcare announces Q1 FY27 Financial Results".
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 25.81% on 30 June 2026. This compares with 25.72% on 31 March 2026, a change of +0.09 percentage points.
The filing reported 41 MF/UTI holders.
Research & Brokerage Views
Recommended buying hospital sector stocks including Fortis, highlighting favourable structural upside across leading healthcare providers.
Upgraded shares to a Buy rating following financial performance updates with a revised target price.
What to Watch Next
- Execution progress and construction milestones for the 400+ bedded Ashok Vihar hospital project.
- Developments regarding the independent forensic audit ordered by the Supreme Court.
- Cash volume and delivery percentage trends relative to the 20-day average volume of ~1.05x.
- Upcoming quarterly financial results and management commentary on operational bed capacity.
Other Dated Coverage
- Why Fortis Healthcare Shares Fell 2.70% Today: Key Drivers | 5 October 2026 — 5 October 2026
- Why Fortis Healthcare Shares Fall 6.33% Today to 52-Week Lows | 30 September 2026 — 30 September 2026
More Fortis Healthcare news and dated analysis →
Frequently Asked Questions
What is the latest Fortis Healthcare company news?
The Supreme Court of India disposed of the Special Leave Petition filed by Fortis Healthcare challenging the Delhi High Court's order directing a forensic audit. The apex court allowed the forensic audit to proceed independently while clarifying that prior observations in the judgment were tentative and shall not influence the audit outcome.
How strong was Fortis Healthcare’s trading volume?
18.17 lakh shares traded, 1.05 times the 20-day average daily volume. The price and volume data are dated 7 October 2026 · 03:15 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 June 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.